Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2018

View Archived Issues

Novartis studies LHC-165 alone and with PDR-001 in advanced malignancies

vTv reports Part B results from STEADFAST study of azeliragon in mild Alzheimer's disease

Discovery and characterization of BWC-0977, a dual bacterial topoisomerase inhibitor

Application for Furoscix receives complete response letter from the FDA

Seattle Genetics doses first patient in phase II study of tisotumab vedotin for cervical cancer

Researchers present phase I data for neoadjuvant anti-OX40 therapy with MEDI-6469 in HNSCC

First patient dosed in phase I study of MET-409

Vistusertib administration feasible prior to radical prostatectomy

Flex Pharma stops two phase II clinical studies of FLX-787

First-in-human data demonstrate early signs of antitumor activity for BI-836880

FDA approves moxidectin to treat river blindness

CFDA grants priority review to Pharnext's PXT-3003 for CMT1A

Improved pharmacokinetic properties of trans-translation inhibitors efficacious against gonorrhea

Sage and Shionogi enter strategic collaboration for SAGE-217 in Japan, Taiwan and South Korea

BridgeBio Pharma launches CoA Therapeutics

FDA approves Keytruda for refractory or relapsed primary mediastinal large B-cell lymphoma

Prana opens enrollment in phase I study of PBT-434

Sun BioPharma announces dosing of first patients in second clinical study of SBP-101

Subcutaneous efgartigimod has comparable characteristics to intravenous formulation in phase I study

Long-term articular cartilage structure modification seen with sprifermin in knee osteoarthritis

Verseon prepares for phase I study of oral anticoagulant VE-1902

Allos initiates phase I RSV challenge study with JNJ-64417184

Phase II results presented from KEYNOTE-158 study of pembrolizumab in SCLC